12:00 AM
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MBI 853NL: Began Phase Ib trial

Micrologix Biotech Inc. (TSE:MBI; MGIXF), Vancouver, B.C.
Product: MBI 853NL
Business: Infectious diseases
Therapeutic category: Bacterial infection
Target: Bacterial cell membrane

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >